Oncodesign Precision Medicine (OPM) SAS manufactures precision medicine. It has built a unique precision medicine platform dedicated to cancerous diseases and other diseases without therapeutic solution. Its innovative platform for the selection of new therapeutic targets has been developed on the basis of patient data and through a novel approach using Artificial Intelligence. The company was founded on December 15, 2020 and is headquartered in Dijon, France.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company